Back to News & Events
The TransMedics® Organ Care System (OCS™) Heart Technology Was Used to Perform The World’s First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent’s Hospital in Sydney, Australia
Andover, Mass. - October 24, 2014
TransMedics announces that its OCS™ Heart technology was used successfully to preserve and assess the world’s first series of three successful adult heart transplant procedures from hearts donated from donors after circulatory death (DCD) by the St. Vincent’s Hospital Heart Transplant team. All patients who received these groundbreaking transplants have recovered very well. This achievement represents a pivotal new milestone in heart transplantation worldwide and it was carried out following pioneering basic and translational research undertaken by the Victor Chang Cardiac Research Institute and St Vincent’s Hospital using the OCS™ Heart technology.
These hearts were retrieved from donors whose hearts had stopped beating in the body of the donor. Currently, these DCD donors are not considered for heart transplantation due to the limitations of the cold storage preservation technique. These hearts were retrieved, resuscitated to a normal beating state and clinically assessed using the TransMedics OCS™ Heart technology. The OCS™ technology platform is the only medical device capable of maintaining donor organs in near physiologic and functioning state outside of the human body from the time the organ is removed from the donor until its ready to be transplanted into a suitable recipient.
The OCS™ Heart system was paramount to the success of this clinical milestone in heart transplantation as it enabled us to fully assess the donor heart function and metabolic state before transplantation, said Dr. Kumud Dhital, Prof. of Cardiothoracic Surgery at St. Vincent’s Hospital and the lead surgeon who performed the DCD heart transplants.
The ability to safely transplant a donor heart from DCD donors could be a paradigm shift to potentially increase the pool of viable donor hearts to help more patients suffering from end-stage heart failure, said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc. We are actively engaged in 4 large pivotal trials for hearts, lungs and livers in the U.S. to bring the revolutionary OCS™ technology to the U.S. market hopefully starting in 2015, said Dr. Hassanein.
What is the TransMedics Organ Care System (OCS™)?
TransMedics has developed the world’s only portable medical device capable of overcoming the limitations of cold storage for organ transplantation. The OCS™ technology was designed to provide a comprehensive solution to all three key limitations of the cold storage technique, as it:
These unique capabilities of the OCS technology have the potential to:
About TransMedics, Inc.